Clinical trial · Interventional
Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient
Multimodal Deep Learning Radiomic Nomogram for Evaluation of Response to Cetuximab in Patient With Colorectal Cancer Liver Metastasis
NCT05873972CI-TRIAL-00066651unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Establishment and validation of the deep learning model of Cetuximab efficacy in simultaneous RAS wild unresectable CRLM patients
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer Liver Metastases | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cetuximab | Drug | Cetuximab | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- ARM A
- description
- Chemotherapy regimens are determined based on the clinical experience of specialists
- interventionNames
- Drug: Cetuximab
- type
- EXPERIMENTAL
- label
- ARM B
- description
- Chemotherapy regimens are determined based on the multimodal deep learning signature
- interventionNames
- Drug: Cetuximab
Primary outcomes (1)
- measure
- response rate
- timeFrame
- 6 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 18-75 years; 2. Histologically proven colorectal adenocarcinoma; 3. Simultaneous liver-limited metastases; 4. Initially unresectable liver metastases determined by a local MDT; 5. Life expectancy of \> 6 months; 6. RAS and BRAF V600E wild-type; 7. ECOG 0-1; 8. Available CT imaging before treatment. Exclusion Criteria: 1. Previous systemic treatment for metastatic disease; 2. Previous surgery for metastatic disease; 3. Extrahepatic metastases; 4. Unresectable primary tumor; 5. Major cardiovascular events (myocardial infarction, severe/unstable angina, congestive heart failure, CVA) within 12 months before randomisation; 6. Acute or subacute intestinal obstruction; 7. Second primary malignancy within the past 5 years; 8. Drug or alcohol abuse; 9. No legal capacity or limited legal capacity; 10. Uncontrolled hypertension, or unsatisfactory blood pressure control with ≥3 antihypertensive drugs;
References
Publications (0)
Data not yet available
No reference posted for this study.